Low cerebrospinal fluid glutamate and glycine in refractory affective disorder

被引:104
作者
Frye, Mark A.
Tsai, Guochuan E.
Huggins, Teresa
Coyle, Joseph T.
Post, Robert M.
机构
[1] Univ Calif Los Angeles, Dept Psychiat, Los Angeles Neuropsychiat Inst, Sch Med, Los Angeles, CA USA
[2] Univ Calif Los Angeles, Harbor UCLA Med Ctr, Dept Psychiat, Sch Med, Torrance, CA USA
[3] NIMH, Biol Psychiat Branch, Bethesda, MD 20892 USA
[4] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA
关键词
glutamate; glycine; mood disorders;
D O I
10.1016/j.biopsych.2006.01.024
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Glutamatergic dysregulation has been documented in schizophrenia but has received less systematic study in affective illness. Methods: Cerebrospinal fluid (CSF) levels of the excitatory amino acids glutamate (Glu) and aspartate (Asp) and the N-metbyl-D-aspartate (NAIDA) receptor modulator, glycine (GLY) were measured by high performance liquid chromatography in 32 patients with refractory affective disorder (16 female/16 male, 12 bipolar 1, 12 bipolar H, and 8 unipolar) and in 14 age-matched controls. Results: There was a significant reduction in CSF glutamate and glycine in patients versus controls. A diagnosis by sex interaction was present for CSF glycine with lower levels in female patients compared to female controls. Levels of the excitatory amino acids were highly inter-correlated in patients, but not in controls. In patients studied after 6 weeks of lamotrigine, there was a trend for CSF glutamate levels to increase. Conclusions: These data suggest that in patients with refractory affective disorder, excitatory amino acids are dysregulated, as exemplified both by the decreased CSF glutamate and glycine and their high intercorrelation compared to controls. Further controlled study of glutamatergic dysregulation and its relationship to the pathophysiology of affective disorders and potential mechanism of action of mood stabilizers appears indicated.
引用
收藏
页码:162 / 166
页数:5
相关论文
共 46 条
  • [1] ALTAMURA CA, 1993, AM J PSYCHIAT, V150, P1731
  • [2] Antidepressant effects of ketamine in depressed patients
    Berman, RM
    Cappiello, A
    Anand, A
    Oren, DA
    Heninger, GR
    Charney, DS
    Krystal, JH
    [J]. BIOLOGICAL PSYCHIATRY, 2000, 47 (04) : 351 - 354
  • [3] Neuronal pathology in the hippocampal area of patients with bipolar disorder: A study with proton magnetic resonance spectroscopic imaging
    Bertolino, A
    Frye, M
    Callicott, JH
    Mattay, VS
    Rakow, R
    Shelton-Repella, J
    Post, R
    Weinberger, DR
    [J]. BIOLOGICAL PSYCHIATRY, 2003, 53 (10) : 906 - 913
  • [4] Hippocampal neurochemical pathology in patients at first episode of affective psychosis: a proton magnetic resonance spectroscopic imaging study
    Blasi, G
    Bertolino, A
    Brudaglio, F
    Sciota, D
    Altamura, M
    Antonucci, N
    Scarabino, T
    Weinberger, DR
    Nardini, M
    [J]. PSYCHIATRY RESEARCH-NEUROIMAGING, 2004, 131 (02) : 95 - 105
  • [5] BUNNEY WE, 1963, ARCH GEN PSYCHIAT, V9, P280
  • [6] Castillo M, 2000, AM J NEURORADIOL, V21, P832
  • [7] Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression
    Choudary, PV
    Molnar, M
    Evans, SJ
    Tomita, H
    Li, JZ
    Vawter, MP
    Myers, RM
    Bunney, WE
    Akil, H
    Watson, SJ
    Jones, EG
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (43) : 15653 - 15658
  • [8] Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia
    Coyle, JT
    Tsai, G
    Goff, D
    [J]. GLUTAMATE AND DISORDERS OF COGNITION AND MOTIVATION, 2003, 1003 : 318 - 327
  • [9] Lower concentration of hippocampal N-acetylaspartate in familial bipolar I disorder
    Deicken, RF
    Pegues, MP
    Anzalone, S
    Feiwell, R
    Soher, B
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2003, 160 (05) : 873 - 882
  • [10] A GLUTAMATERGIC HYPOTHESIS OF SCHIZOPHRENIA - RATIONALE FOR PHARMACOTHERAPY WITH GLYCINE
    DEUTSCH, SI
    MASTROPAOLO, J
    SCHWARTZ, BL
    ROSSE, RB
    MORIHISA, JM
    [J]. CLINICAL NEUROPHARMACOLOGY, 1989, 12 (01) : 1 - 13